NeuroOne Medical Technologies (NASDAQ:NMTC) Director Mark Christianson Sells 10,000 Shares of Stock

Posted by Brenda Bartman on Jul 3rd, 2026

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC – Get Free Report) Director Mark Christianson sold 10,000 shares of NeuroOne Medical Technologies stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $3.18, for a total value of $31,800.00. Following the completion of the sale, the director owned 20,692 shares of the company’s stock, valued at $65,800.56. This trade represents a 32.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

NeuroOne Medical Technologies Price Performance

NASDAQ NMTC opened at $3.00 on Friday. NeuroOne Medical Technologies Corporation has a 12 month low of $2.89 and a 12 month high of $6.96. The company has a 50-day moving average of $3.84 and a 200-day moving average of $4.39. The company has a market cap of $26.10 million, a P/E ratio of -3.53 and a beta of 0.54.

NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) last released its earnings results on Tuesday, May 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.02). NeuroOne Medical Technologies had a negative return on equity of 99.43% and a negative net margin of 68.35%.The company had revenue of $1.86 million during the quarter, compared to analyst estimates of $2.58 million. As a group, equities research analysts anticipate that NeuroOne Medical Technologies Corporation will post -0.36 EPS for the current year.

Institutional Trading of NeuroOne Medical Technologies

Institutional investors have recently modified their holdings of the company. Legato Capital Management LLC purchased a new position in NeuroOne Medical Technologies in the fourth quarter valued at approximately $34,000. Squarepoint Ops LLC purchased a new stake in NeuroOne Medical Technologies during the fourth quarter worth approximately $36,000. Susquehanna International Group LLP purchased a new stake in NeuroOne Medical Technologies during the third quarter worth approximately $47,000. XTX Topco Ltd acquired a new stake in shares of NeuroOne Medical Technologies in the second quarter worth $51,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of NeuroOne Medical Technologies in the first quarter worth $84,000. Hedge funds and other institutional investors own 16.07% of the company’s stock.

Wall Street Analyst Weigh In

NMTC has been the topic of a number of research analyst reports. LADENBURG THALM/SH SH lifted their price target on shares of NeuroOne Medical Technologies from $1.60 to $8.00 and gave the company a “buy” rating in a report on Wednesday, May 13th. Zacks Research downgraded NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a report on Friday, March 13th. Finally, Weiss Ratings lowered NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, May 11th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, NeuroOne Medical Technologies has a consensus rating of “Hold” and an average target price of $11.67.

Read Our Latest Stock Report on NMTC

About NeuroOne Medical Technologies

(Get Free Report)

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.